 | • レポートコード：MRC2-11QY06724 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、116ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はゴーシェ病治療薬のグローバル市場について調査・分析したレポートです。種類別（酵素置換、グルコシルセラミドシンターゼ阻害剤、骨粗鬆症薬）市場規模、用途別（I型ゴーシェ病、II型ゴーシェ病、III型ゴーシェ病）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別ゴーシェ病治療薬の競争状況、市場シェア ・世界のゴーシェ病治療薬市場：種類別市場規模 2015年-2020年（酵素置換、グルコシルセラミドシンターゼ阻害剤、骨粗鬆症薬） ・世界のゴーシェ病治療薬市場：種類別市場規模予測 2021年-2026年（酵素置換、グルコシルセラミドシンターゼ阻害剤、骨粗鬆症薬） ・世界のゴーシェ病治療薬市場：用途別市場規模 2015年-2020年（I型ゴーシェ病、II型ゴーシェ病、III型ゴーシェ病） ・世界のゴーシェ病治療薬市場：用途別市場規模予測 2021年-2026年（I型ゴーシェ病、II型ゴーシェ病、III型ゴーシェ病） ・北米のゴーシェ病治療薬市場分析：米国、カナダ ・ヨーロッパのゴーシェ病治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのゴーシェ病治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のゴーシェ病治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのゴーシェ病治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Dong-A-Socio Holdings、Genzyme Corporation、ExSAR Corporation、Neuraltus Pharmaceuticals、Amicus Therapeutics、JCR Pharmaceuticals、Lixte Biotechnology Holdings、Protalix BioTherapeutics、Greenovation Biotech ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Gaucher Disease Drugs Market
The global Gaucher Disease Drugs market size is projected to reach US$ 1330 million by 2026, from US$ 1321 million in 2020, at a CAGR of 0.6%% during 2021-2026.
Global Gaucher Disease Drugs Scope and Market Size
Gaucher Disease Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Gaucher Disease Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Gaucher Disease Drugs market is segmented into
Replace Enzymes
Glucosylceramide Synthase Inhibitors
Osteoporosis Drugs
Segment by Application, the Gaucher Disease Drugs market is segmented into
Type I Gaucher Disease
Type II Gaucher Disease
Type III Gaucher Disease
Regional and Country-level Analysis
The Gaucher Disease Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Gaucher Disease Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Gaucher Disease Drugs Market Share Analysis
Gaucher Disease Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Gaucher Disease Drugs business, the date to enter into the Gaucher Disease Drugs market, Gaucher Disease Drugs product introduction, recent developments, etc.
The major vendors covered:
Dong-A-Socio Holdings
Genzyme Corporation
ExSAR Corporation
Neuraltus Pharmaceuticals
Amicus Therapeutics
JCR Pharmaceuticals
Lixte Biotechnology Holdings
Protalix BioTherapeutics
Greenovation Biotech
1 Study Coverage
1.1 Gaucher Disease Drugs Product Introduction
1.2 Market Segments
1.3 Key Gaucher Disease Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Gaucher Disease Drugs Market Size Growth Rate by Type
1.4.2 Replace Enzymes
1.4.3 Glucosylceramide Synthase Inhibitors
1.4.4 Osteoporosis Drugs
1.5 Market by Application
1.5.1 Global Gaucher Disease Drugs Market Size Growth Rate by Application
1.5.2 Type I Gaucher Disease
1.5.3 Type II Gaucher Disease
1.5.4 Type III Gaucher Disease
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Gaucher Disease Drugs Market Size, Estimates and Forecasts
2.1.1 Global Gaucher Disease Drugs Revenue 2015-2026
2.1.2 Global Gaucher Disease Drugs Sales 2015-2026
2.2 Global Gaucher Disease Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Gaucher Disease Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Gaucher Disease Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Gaucher Disease Drugs Competitor Landscape by Players
3.1 Gaucher Disease Drugs Sales by Manufacturers
3.1.1 Gaucher Disease Drugs Sales by Manufacturers (2015-2020)
3.1.2 Gaucher Disease Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Gaucher Disease Drugs Revenue by Manufacturers
3.2.1 Gaucher Disease Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Gaucher Disease Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Gaucher Disease Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Gaucher Disease Drugs Revenue in 2019
3.2.5 Global Gaucher Disease Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Gaucher Disease Drugs Price by Manufacturers
3.4 Gaucher Disease Drugs Manufacturing Base Distribution, Product Types
3.4.1 Gaucher Disease Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Gaucher Disease Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Gaucher Disease Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Gaucher Disease Drugs Market Size by Type (2015-2020)
4.1.1 Global Gaucher Disease Drugs Sales by Type (2015-2020)
4.1.2 Global Gaucher Disease Drugs Revenue by Type (2015-2020)
4.1.3 Gaucher Disease Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Gaucher Disease Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Gaucher Disease Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Gaucher Disease Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Gaucher Disease Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Gaucher Disease Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Gaucher Disease Drugs Market Size by Application (2015-2020)
5.1.1 Global Gaucher Disease Drugs Sales by Application (2015-2020)
5.1.2 Global Gaucher Disease Drugs Revenue by Application (2015-2020)
5.1.3 Gaucher Disease Drugs Price by Application (2015-2020)
5.2 Gaucher Disease Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Gaucher Disease Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Gaucher Disease Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Gaucher Disease Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Gaucher Disease Drugs by Country
6.1.1 North America Gaucher Disease Drugs Sales by Country
6.1.2 North America Gaucher Disease Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Gaucher Disease Drugs Market Facts & Figures by Type
6.3 North America Gaucher Disease Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Gaucher Disease Drugs by Country
7.1.1 Europe Gaucher Disease Drugs Sales by Country
7.1.2 Europe Gaucher Disease Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Gaucher Disease Drugs Market Facts & Figures by Type
7.3 Europe Gaucher Disease Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Gaucher Disease Drugs by Region
8.1.1 Asia Pacific Gaucher Disease Drugs Sales by Region
8.1.2 Asia Pacific Gaucher Disease Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Gaucher Disease Drugs Market Facts & Figures by Type
8.3 Asia Pacific Gaucher Disease Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Gaucher Disease Drugs by Country
9.1.1 Latin America Gaucher Disease Drugs Sales by Country
9.1.2 Latin America Gaucher Disease Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Gaucher Disease Drugs Market Facts & Figures by Type
9.3 Central & South America Gaucher Disease Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Gaucher Disease Drugs by Country
10.1.1 Middle East and Africa Gaucher Disease Drugs Sales by Country
10.1.2 Middle East and Africa Gaucher Disease Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Gaucher Disease Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Gaucher Disease Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 Dong-A-Socio Holdings
11.1.1 Dong-A-Socio Holdings Corporation Information
11.1.2 Dong-A-Socio Holdings Description and Business Overview
11.1.3 Dong-A-Socio Holdings Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Dong-A-Socio Holdings Gaucher Disease Drugs Products Offered
11.1.5 Dong-A-Socio Holdings Related Developments
11.2 Genzyme Corporation
11.2.1 Genzyme Corporation Corporation Information
11.2.2 Genzyme Corporation Description and Business Overview
11.2.3 Genzyme Corporation Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Genzyme Corporation Gaucher Disease Drugs Products Offered
11.2.5 Genzyme Corporation Related Developments
11.3 ExSAR Corporation
11.3.1 ExSAR Corporation Corporation Information
11.3.2 ExSAR Corporation Description and Business Overview
11.3.3 ExSAR Corporation Sales, Revenue and Gross Margin (2015-2020)
11.3.4 ExSAR Corporation Gaucher Disease Drugs Products Offered
11.3.5 ExSAR Corporation Related Developments
11.4 Neuraltus Pharmaceuticals
11.4.1 Neuraltus Pharmaceuticals Corporation Information
11.4.2 Neuraltus Pharmaceuticals Description and Business Overview
11.4.3 Neuraltus Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Neuraltus Pharmaceuticals Gaucher Disease Drugs Products Offered
11.4.5 Neuraltus Pharmaceuticals Related Developments
11.5 Amicus Therapeutics
11.5.1 Amicus Therapeutics Corporation Information
11.5.2 Amicus Therapeutics Description and Business Overview
11.5.3 Amicus Therapeutics Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Amicus Therapeutics Gaucher Disease Drugs Products Offered
11.5.5 Amicus Therapeutics Related Developments
11.6 JCR Pharmaceuticals
11.6.1 JCR Pharmaceuticals Corporation Information
11.6.2 JCR Pharmaceuticals Description and Business Overview
11.6.3 JCR Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.6.4 JCR Pharmaceuticals Gaucher Disease Drugs Products Offered
11.6.5 JCR Pharmaceuticals Related Developments
11.7 Lixte Biotechnology Holdings
11.7.1 Lixte Biotechnology Holdings Corporation Information
11.7.2 Lixte Biotechnology Holdings Description and Business Overview
11.7.3 Lixte Biotechnology Holdings Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Lixte Biotechnology Holdings Gaucher Disease Drugs Products Offered
11.7.5 Lixte Biotechnology Holdings Related Developments
11.8 Protalix BioTherapeutics
11.8.1 Protalix BioTherapeutics Corporation Information
11.8.2 Protalix BioTherapeutics Description and Business Overview
11.8.3 Protalix BioTherapeutics Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Protalix BioTherapeutics Gaucher Disease Drugs Products Offered
11.8.5 Protalix BioTherapeutics Related Developments
11.9 Greenovation Biotech
11.9.1 Greenovation Biotech Corporation Information
11.9.2 Greenovation Biotech Description and Business Overview
11.9.3 Greenovation Biotech Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Greenovation Biotech Gaucher Disease Drugs Products Offered
11.9.5 Greenovation Biotech Related Developments
11.1 Dong-A-Socio Holdings
11.1.1 Dong-A-Socio Holdings Corporation Information
11.1.2 Dong-A-Socio Holdings Description and Business Overview
11.1.3 Dong-A-Socio Holdings Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Dong-A-Socio Holdings Gaucher Disease Drugs Products Offered
11.1.5 Dong-A-Socio Holdings Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Gaucher Disease Drugs Market Estimates and Projections by Region
12.1.1 Global Gaucher Disease Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Gaucher Disease Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Gaucher Disease Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Gaucher Disease Drugs Sales Forecast (2021-2026)
12.2.2 North America: Gaucher Disease Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Gaucher Disease Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Gaucher Disease Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Gaucher Disease Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Gaucher Disease Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Gaucher Disease Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Gaucher Disease Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Gaucher Disease Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Gaucher Disease Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Gaucher Disease Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Gaucher Disease Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Gaucher Disease Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Gaucher Disease Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Gaucher Disease Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Gaucher Disease Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Gaucher Disease Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Gaucher Disease Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Gaucher Disease Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Gaucher Disease Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Gaucher Disease Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Gaucher Disease Drugs Market Segments
Table 2. Ranking of Global Top Gaucher Disease Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Gaucher Disease Drugs Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Replace Enzymes
Table 5. Major Manufacturers of Glucosylceramide Synthase Inhibitors
Table 6. Major Manufacturers of Osteoporosis Drugs
Table 7. Global Gaucher Disease Drugs Market Size Growth Rate by Application 2020-2026 (K Units)
Table 8. Global Gaucher Disease Drugs Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 9. Global Gaucher Disease Drugs Sales by Regions 2015-2020 (K Units)
Table 10. Global Gaucher Disease Drugs Sales Market Share by Regions (2015-2020)
Table 11. Global Gaucher Disease Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 12. Global Gaucher Disease Drugs Sales by Manufacturers (2015-2020) (K Units)
Table 13. Global Gaucher Disease Drugs Sales Share by Manufacturers (2015-2020)
Table 14. Global Gaucher Disease Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 15. Global Gaucher Disease Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Gaucher Disease Drugs as of 2019)
Table 16. Gaucher Disease Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 17. Gaucher Disease Drugs Revenue Share by Manufacturers (2015-2020)
Table 18. Key Manufacturers Gaucher Disease Drugs Price (2015-2020) (USD/Unit)
Table 19. Gaucher Disease Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 20. Manufacturers Gaucher Disease Drugs Product Type
Table 21. Date of International Manufacturers Enter into Gaucher Disease Drugs Market
Table 22. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 23. Global Gaucher Disease Drugs Sales by Type (2015-2020) (K Units)
Table 24. Global Gaucher Disease Drugs Sales Share by Type (2015-2020)
Table 25. Global Gaucher Disease Drugs Revenue by Type (2015-2020) (US$ Million)
Table 26. Global Gaucher Disease Drugs Revenue Share by Type (2015-2020)
Table 27. Gaucher Disease Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 28. Global Gaucher Disease Drugs Sales by Application (2015-2020) (K Units)
Table 29. Global Gaucher Disease Drugs Sales Share by Application (2015-2020)
Table 30. North America Gaucher Disease Drugs Sales by Country (2015-2020) (K Units)
Table 31. North America Gaucher Disease Drugs Sales Market Share by Country (2015-2020)
Table 32. North America Gaucher Disease Drugs Revenue by Country (2015-2020) (US$ Million)
Table 33. North America Gaucher Disease Drugs Revenue Market Share by Country (2015-2020)
Table 34. North America Gaucher Disease Drugs Sales by Type (2015-2020) (K Units)
Table 35. North America Gaucher Disease Drugs Sales Market Share by Type (2015-2020)
Table 36. North America Gaucher Disease Drugs Sales by Application (2015-2020) (K Units)
Table 37. North America Gaucher Disease Drugs Sales Market Share by Application (2015-2020)
Table 38. Europe Gaucher Disease Drugs Sales by Country (2015-2020) (K Units)
Table 39. Europe Gaucher Disease Drugs Sales Market Share by Country (2015-2020)
Table 40. Europe Gaucher Disease Drugs Revenue by Country (2015-2020) (US$ Million)
Table 41. Europe Gaucher Disease Drugs Revenue Market Share by Country (2015-2020)
Table 42. Europe Gaucher Disease Drugs Sales by Type (2015-2020) (K Units)
Table 43. Europe Gaucher Disease Drugs Sales Market Share by Type (2015-2020)
Table 44. Europe Gaucher Disease Drugs Sales by Application (2015-2020) (K Units)
Table 45. Europe Gaucher Disease Drugs Sales Market Share by Application (2015-2020)
Table 46. Asia Pacific Gaucher Disease Drugs Sales by Region (2015-2020) (K Units)
Table 47. Asia Pacific Gaucher Disease Drugs Sales Market Share by Region (2015-2020)
Table 48. Asia Pacific Gaucher Disease Drugs Revenue by Region (2015-2020) (US$ Million)
Table 49. Asia Pacific Gaucher Disease Drugs Revenue Market Share by Region (2015-2020)
Table 50. Asia Pacific Gaucher Disease Drugs Sales by Type (2015-2020) (K Units)
Table 51. Asia Pacific Gaucher Disease Drugs Sales Market Share by Type (2015-2020)
Table 52. Asia Pacific Gaucher Disease Drugs Sales by Application (2015-2020) (K Units)
Table 53. Asia Pacific Gaucher Disease Drugs Sales Market Share by Application (2015-2020)
Table 54. Latin America Gaucher Disease Drugs Sales by Country (2015-2020) (K Units)
Table 55. Latin America Gaucher Disease Drugs Sales Market Share by Country (2015-2020)
Table 56. Latin Americaa Gaucher Disease Drugs Revenue by Country (2015-2020) (US$ Million)
Table 57. Latin America Gaucher Disease Drugs Revenue Market Share by Country (2015-2020)
Table 58. Latin America Gaucher Disease Drugs Sales by Type (2015-2020) (K Units)
Table 59. Latin America Gaucher Disease Drugs Sales Market Share by Type (2015-2020)
Table 60. Latin America Gaucher Disease Drugs Sales by Application (2015-2020) (K Units)
Table 61. Latin America Gaucher Disease Drugs Sales Market Share by Application (2015-2020)
Table 62. Middle East and Africa Gaucher Disease Drugs Sales by Country (2015-2020) (K Units)
Table 63. Middle East and Africa Gaucher Disease Drugs Sales Market Share by Country (2015-2020)
Table 64. Middle East and Africa Gaucher Disease Drugs Revenue by Country (2015-2020) (US$ Million)
Table 65. Middle East and Africa Gaucher Disease Drugs Revenue Market Share by Country (2015-2020)
Table 66. Middle East and Africa Gaucher Disease Drugs Sales by Type (2015-2020) (K Units)
Table 67. Middle East and Africa Gaucher Disease Drugs Sales Market Share by Type (2015-2020)
Table 68. Middle East and Africa Gaucher Disease Drugs Sales by Application (2015-2020) (K Units)
Table 69. Middle East and Africa Gaucher Disease Drugs Sales Market Share by Application (2015-2020)
Table 70. Dong-A-Socio Holdings Corporation Information
Table 71. Dong-A-Socio Holdings Description and Major Businesses
Table 72. Dong-A-Socio Holdings Gaucher Disease Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 73. Dong-A-Socio Holdings Product
Table 74. Dong-A-Socio Holdings Recent Development
Table 75. Genzyme Corporation Corporation Information
Table 76. Genzyme Corporation Description and Major Businesses
Table 77. Genzyme Corporation Gaucher Disease Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 78. Genzyme Corporation Product
Table 79. Genzyme Corporation Recent Development
Table 80. ExSAR Corporation Corporation Information
Table 81. ExSAR Corporation Description and Major Businesses
Table 82. ExSAR Corporation Gaucher Disease Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 83. ExSAR Corporation Product
Table 84. ExSAR Corporation Recent Development
Table 85. Neuraltus Pharmaceuticals Corporation Information
Table 86. Neuraltus Pharmaceuticals Description and Major Businesses
Table 87. Neuraltus Pharmaceuticals Gaucher Disease Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 88. Neuraltus Pharmaceuticals Product
Table 89. Neuraltus Pharmaceuticals Recent Development
Table 90. Amicus Therapeutics Corporation Information
Table 91. Amicus Therapeutics Description and Major Businesses
Table 92. Amicus Therapeutics Gaucher Disease Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 93. Amicus Therapeutics Product
Table 94. Amicus Therapeutics Recent Development
Table 95. JCR Pharmaceuticals Corporation Information
Table 96. JCR Pharmaceuticals Description and Major Businesses
Table 97. JCR Pharmaceuticals Gaucher Disease Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 98. JCR Pharmaceuticals Product
Table 99. JCR Pharmaceuticals Recent Development
Table 100. Lixte Biotechnology Holdings Corporation Information
Table 101. Lixte Biotechnology Holdings Description and Major Businesses
Table 102. Lixte Biotechnology Holdings Gaucher Disease Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 103. Lixte Biotechnology Holdings Product
Table 104. Lixte Biotechnology Holdings Recent Development
Table 105. Protalix BioTherapeutics Corporation Information
Table 106. Protalix BioTherapeutics Description and Major Businesses
Table 107. Protalix BioTherapeutics Gaucher Disease Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 108. Protalix BioTherapeutics Product
Table 109. Protalix BioTherapeutics Recent Development
Table 110. Greenovation Biotech Corporation Information
Table 111. Greenovation Biotech Description and Major Businesses
Table 112. Greenovation Biotech Gaucher Disease Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 113. Greenovation Biotech Product
Table 114. Greenovation Biotech Recent Development
Table 115. Global Gaucher Disease Drugs Sales Forecast by Regions (2021-2026) (K Units)
Table 116. Global Gaucher Disease Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 117. Global Gaucher Disease Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 118. Global Gaucher Disease Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 119. North America: Gaucher Disease Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 120. North America: Gaucher Disease Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 121. Europe: Gaucher Disease Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 122. Europe: Gaucher Disease Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 123. Asia Pacific: Gaucher Disease Drugs Sales Forecast by Region (2021-2026) (K Units)
Table 124. Asia Pacific: Gaucher Disease Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 125. Latin America: Gaucher Disease Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 126. Latin America: Gaucher Disease Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 127. Middle East and Africa: Gaucher Disease Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 128. Middle East and Africa: Gaucher Disease Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 129. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 130. Key Challenges
Table 131. Market Risks
Table 132. Main Points Interviewed from Key Gaucher Disease Drugs Players
Table 133. Gaucher Disease Drugs Customers List
Table 134. Gaucher Disease Drugs Distributors List
Table 135. Research Programs/Design for This Report
Table 136. Key Data Information from Secondary Sources
Table 137. Key Data Information from Primary Sources
List of Figures
Figure 1. Gaucher Disease Drugs Product Picture
Figure 2. Global Gaucher Disease Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Replace Enzymes Product Picture
Figure 4. Glucosylceramide Synthase Inhibitors Product Picture
Figure 5. Osteoporosis Drugs Product Picture
Figure 6. Global Gaucher Disease Drugs Sales Market Share by Application in 2020 & 2026
Figure 7. Type I Gaucher Disease
Figure 8. Type II Gaucher Disease
Figure 9. Type III Gaucher Disease
Figure 10. Gaucher Disease Drugs Report Years Considered
Figure 11. Global Gaucher Disease Drugs Market Size 2015-2026 (US$ Million)
Figure 12. Global Gaucher Disease Drugs Sales 2015-2026 (K Units)
Figure 13. Global Gaucher Disease Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 14. Global Gaucher Disease Drugs Sales Market Share by Region (2015-2020)
Figure 15. Global Gaucher Disease Drugs Sales Market Share by Region in 2019
Figure 16. Global Gaucher Disease Drugs Revenue Market Share by Region (2015-2020)
Figure 17. Global Gaucher Disease Drugs Revenue Market Share by Region in 2019
Figure 18. Global Gaucher Disease Drugs Sales Share by Manufacturer in 2019
Figure 19. The Top 10 and 5 Players Market Share by Gaucher Disease Drugs Revenue in 2019
Figure 20. Gaucher Disease Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 21. Global Gaucher Disease Drugs Sales Market Share by Type (2015-2020)
Figure 22. Global Gaucher Disease Drugs Sales Market Share by Type in 2019
Figure 23. Global Gaucher Disease Drugs Revenue Market Share by Type (2015-2020)
Figure 24. Global Gaucher Disease Drugs Revenue Market Share by Type in 2019
Figure 25. Global Gaucher Disease Drugs Market Share by Price Range (2015-2020)
Figure 26. Global Gaucher Disease Drugs Sales Market Share by Application (2015-2020)
Figure 27. Global Gaucher Disease Drugs Sales Market Share by Application in 2019
Figure 28. Global Gaucher Disease Drugs Revenue Market Share by Application (2015-2020)
Figure 29. Global Gaucher Disease Drugs Revenue Market Share by Application in 2019
Figure 30. North America Gaucher Disease Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 31. North America Gaucher Disease Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 32. North America Gaucher Disease Drugs Sales Market Share by Country in 2019
Figure 33. North America Gaucher Disease Drugs Revenue Market Share by Country in 2019
Figure 34. U.S. Gaucher Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 35. U.S. Gaucher Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 36. Canada Gaucher Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 37. Canada Gaucher Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. North America Gaucher Disease Drugs Market Share by Type in 2019
Figure 39. North America Gaucher Disease Drugs Market Share by Application in 2019
Figure 40. Europe Gaucher Disease Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 41. Europe Gaucher Disease Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 42. Europe Gaucher Disease Drugs Sales Market Share by Country in 2019
Figure 43. Europe Gaucher Disease Drugs Revenue Market Share by Country in 2019
Figure 44. Germany Gaucher Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 45. Germany Gaucher Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 46. France Gaucher Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 47. France Gaucher Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. U.K. Gaucher Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 49. U.K. Gaucher Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. Italy Gaucher Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 51. Italy Gaucher Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Russia Gaucher Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 53. Russia Gaucher Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Europe Gaucher Disease Drugs Market Share by Type in 2019
Figure 55. Europe Gaucher Disease Drugs Market Share by Application in 2019
Figure 56. Asia Pacific Gaucher Disease Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 57. Asia Pacific Gaucher Disease Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 58. Asia Pacific Gaucher Disease Drugs Sales Market Share by Region in 2019
Figure 59. Asia Pacific Gaucher Disease Drugs Revenue Market Share by Region in 2019
Figure 60. China Gaucher Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 61. China Gaucher Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. Japan Gaucher Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 63. Japan Gaucher Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. South Korea Gaucher Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 65. South Korea Gaucher Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. India Gaucher Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 67. India Gaucher Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. Australia Gaucher Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 69. Australia Gaucher Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Taiwan Gaucher Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 71. Taiwan Gaucher Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Indonesia Gaucher Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 73. Indonesia Gaucher Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Thailand Gaucher Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 75. Thailand Gaucher Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Malaysia Gaucher Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 77. Malaysia Gaucher Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Philippines Gaucher Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 79. Philippines Gaucher Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Vietnam Gaucher Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 81. Vietnam Gaucher Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Asia Pacific Gaucher Disease Drugs Market Share by Type in 2019
Figure 83. Asia Pacific Gaucher Disease Drugs Market Share by Application in 2019
Figure 84. Latin America Gaucher Disease Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 85. Latin America Gaucher Disease Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 86. Latin America Gaucher Disease Drugs Sales Market Share by Country in 2019
Figure 87. Latin America Gaucher Disease Drugs Revenue Market Share by Country in 2019
Figure 88. Mexico Gaucher Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 89. Mexico Gaucher Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 90. Brazil Gaucher Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 91. Brazil Gaucher Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Argentina Gaucher Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 93. Argentina Gaucher Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Latin America Gaucher Disease Drugs Market Share by Type in 2019
Figure 95. Latin America Gaucher Disease Drugs Market Share by Application in 2019
Figure 96. Middle East and Africa Gaucher Disease Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 97. Middle East and Africa Gaucher Disease Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 98. Middle East and Africa Gaucher Disease Drugs Sales Market Share by Country in 2019
Figure 99. Middle East and Africa Gaucher Disease Drugs Revenue Market Share by Country in 2019
Figure 100. Turkey Gaucher Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 101. Turkey Gaucher Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 102. Saudi Arabia Gaucher Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 103. Saudi Arabia Gaucher Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. U.A.E Gaucher Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 105. U.A.E Gaucher Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. Middle East and Africa Gaucher Disease Drugs Market Share by Type in 2019
Figure 107. Middle East and Africa Gaucher Disease Drugs Market Share by Application in 2019
Figure 108. North America Gaucher Disease Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 109. North America Gaucher Disease Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 110. Europe Gaucher Disease Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 111. Europe Gaucher Disease Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Asia Pacific Gaucher Disease Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 113. Asia Pacific Gaucher Disease Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Latin America Gaucher Disease Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 115. Latin America Gaucher Disease Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Middle East and Africa Gaucher Disease Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 117. Middle East and Africa Gaucher Disease Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Porter's Five Forces Analysis
Figure 119. Channels of Distribution
Figure 120. Distributors Profiles
Figure 121. Bottom-up and Top-down Approaches for This Report
Figure 122. Data Triangulation
Figure 123. Key Executives Interviewed
ゴーシェ病治療の世界市場（～2026年） Market Analysis and Insights: Global Gaucher Disease Treatment Market The global Gaucher Disease Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Gaucher Disease Treatment Scope and Market Size Gaucher Disease…- クラッベ病治療薬の世界市場（～2026年） Krabbe disease is an uncommon and typically deadly concern of the nervous system. It is an acquired hereditary sickness, which implies that it is passed down in families. Individuals with Krabbe disease are not able to make a sufficient substance called galactosylceramidase, which is expected to mak…
- 重症筋無力症治療薬の世界市場（～2026年） Myasthenia gravis is a neuromuscular disorder that leads to the weakening of skeletal muscles, which are responsible for the movement of the body. This condition occurs due to the impairment of communication between muscles and nerve cells. This impairment causes difficulties in the contraction and …
- 末梢動脈疾患（PAD）薬の世界市場（～2026年） Market Analysis and Insights: Global Peripheral Arterial Disease (PAD) Drugs Market The global Peripheral Arterial Disease (PAD) Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Peripheral Arterial Disease (PAD) D…
- メニエール病治療薬の世界市場（～2026年） Market Analysis and Insights: Global Meniere Disease Drugs Market The global Meniere Disease Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Meniere Disease Drugs Scope and Market Size Meniere Disease Drugs marke…